Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12553039 | 0.84 | NUAK1 (0.41) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL12553377 | 0.84 | AKT1 (0.41) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL9606822 | 0.81 | MAOA (0.41) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL14849268 | 0.81 | NUAK1 (0.39) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL12553313 | 0.80 | ALOX5 (0.48) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL22472340 | 0.79 | SMN1; SMN2 (0.48) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL18704855 | 0.77 | KCNJ1 (0.38) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL12553376 | 0.76 | CYP1A1 (0.50) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL12553375 | 0.75 | CYP1A1 (0.35) | MAOAMAOBAKT1NUAK1IGF1R | |
| SCHEMBL12553493 | 0.74 | IMPDH1 (0.39) | MAOAMAOBAKT1NUAK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9944663-B2 | Process for preparing substituted pentacenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9944663-B2 | Process for preparing substituted pentacenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010046240-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2010-04-29 | — | — | WO | disclosed |
| EP-2134725-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | Merck Patent GmbH (DE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009150074-A1 | SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | BASF SE (DE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2008128618-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128618-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007147782-A2 | OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS | CIBA HOLDING INC. (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | MAOA 1184/4885MAOB 987/4885AKT1 3375/4885 |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOA 3312/4885MAOB 2010/4885AKT1 173/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | MAOA 1184/4885MAOB 987/4885AKT1 3375/4885 |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | FES, PFAS, SLC46A1 | MAOA 2348/4885MAOB 3180/4885AKT1 2894/4885 |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOA 3312/4885MAOB 2010/4885AKT1 173/4885 |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | NR2E3, HCAR3, HRH4 | MAOA 3634/4885MAOB 3321/4885AKT1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.